<<

AAddvvaanncceess iinn MMeeddiiccaall && SSuurrggiiccaall AAnntteerriioorr SSeeggmmeenntt TThheerraappyy J. James Thimons, O.D.,FAAO Optometric Medical Director Ophthalmic Consultants of Connecticut

CCrroossss LLiinnkkiinngg:: NNeeww TTeecchhnnoollooggyy ffoorr aanndd OOlldd DDiisseeaassee KCN Diagnosis Corneal Collagen Cross-Linking Creates chemical bonds between fibers

Floppy Syndrome Cross-Linking is Not New  Hardening of polymers in materials science since 1930s (silicone oil→rubber ball)  Dentists X-linked for decades  Normal aging of connective tissue involves cross-linking and stiffening  Progression of KCN↓ with age as XL↑ We All “Crosslink” as we Grow Up Transplant Risks Before and After Crosslinking CCXXLL iinn KKeerraattooccoonnuuss  Shown safe and effective worldwide  Arrest progress of KCN  Improvement in UCV, BCSVA, CLs  Ideal candidates ≤ 45 y/o, corneal thickness ≥ 400 µm, limited scarring  Minimum age in Europe now 10 y/o CXL and Ectasia  Kannalopoulos, J  Review of CXL post LASIK with ectasia  Analysis at one year – stable – Mild shift  No PK required at two years CXL and PRK  Requires wavefront scan at level 4 reliability  Predictability is less than standard PRK  Contraindicated with apical scar  Post-op similar to standard PRK  CL’s same algorithm

Radial Keratotomy CXL Technique

UV-A Light 370 CXL  Post-operative Care – 1 day, 1 week, & 1 month recommended visits – 4th generation fluoroquinolone qid x 4 days – Durezol or PF taper x 3 weeks – BCL – NPATS Haze?

CXL  Post Epi-On CXL Contact Tx – Soft lens several days – HCL 1 week – Hybrid 2 weeks  Topo’s at 3M/ 6M  Crosslinking can continue up to 6M Indications for Intacs Step 1: Intralase Intacs Channel Creation

Post-Operative Management Issues Managing MGD in the Primary Care Setting  OM3’s  Cycline’s  Hot compresses  Lid Hygiene  Meibomian Gland Expression  Lipiflow Because Not All MGD Is Obvious, Active Disease Identifiication Is Crucial Meibomian Glands

Meibomian Gland Expression  Arita Meibomian Gland Expression System  With or without anesthesia  Grade I-IV  Non- billable  More difficult at the punctal region.

LLiippiiFFllooww // LLiippiiVViieeww AA NNeeww PPaarraaddiiggmm iinn MMeeiibboommiiaann GGllaanndd DDiisseeaassee TTrreeaattmmeenntt Meibomian Gland Expression and Gland Functionality MGD and Lipid Layer Thickness TTeeaarrSScciieennccee®® SSoolluuttiioonn

LipiView® Output

Because Not All MGD Is Obvious, Active Disease Identification Is Crucial Normal Meibomiian Glands Posterior Lid Margin Disease  Clinical Findings – Posterior Lid margin – Inspissation of glands  Erythema & telangiectasia – Pouting of oil – Gland drop out – Rapid tear break up time Bacterial Lipases Breakdown Lipids to Soap Meibomian Glands LipiFlow® Thermal Pulsation System

LipiFlow® Thermal Pulsation System LipiView/ LipiFlow  LipiView – Reimbursement: $ 125.00  Lipiflow – Reimbursement: $1000.00-1,500.00 Point of Care Diagnostic Systems: The Next Step in Anterior Segment Care  RPS Adenodetector  Tear Lab  Inflamma-Dry  LacriPen Laboratory Testing Primary Care: A Paradigm Shift Laboratory Testing Acute Adenoviral Conjunctivitis Clinical Accuracy

AdenoPlus

How to Use AdenoPlus: Four-step Process RPS Adeno Detector Plus InflammaDry InflammaDry: Defining the Role of MMP-9 in Dry Eye? MMP-9 and Dry Eye Severity1 Limit of Detection How to Use InflammaDry: Four-step Process Future Advances in Tear Marker Assessment  Tear markers that currently exist: – Osmolarity – Adenovirus – MMP-9

 IgE, HSV  Alzheimer's  Diabetes  Parkinsons?

Tear Function Screening Questionnaire  Gritty or sandy sensation?  Pain or soreness?  Fluctuating vision?  Occasional Tearing?  Blurred vision while reading?  Discomfort in windy conditions?  Discomfort in air conditioned areas?  Itching?

Possible Testing During Dry Eye Evaluation Tear Break Up Time CCoonnjjuunnccttiivvaall SSttaaiinniinngg

SScchhiirrmmeerr SSttrriippss

Summary Statistics on Tear Osmolarity  Normal subject average: – 296 ± 8 mOsm/L  Dry Eye subject average: – 323 ± 16 mOsm/L

 Normal subject inter-eye difference: – 7 ± 6 mOsm/L  Dry Eye subject inter-eye difference: – 17 ± 15 mOsm/L – Inter-eye difference is the hallmark of DED ( > 8 mOsm/L between eyes)1 Osmollariity iin the Diiagnosiis of Dry Eye Diisease  Osmolarity is the “gold standard” test for Dry Eye – 45 years peer reviewed research – Osmolarity has been added to definition of Dry Eye – Global marker of Dry Eye, indicating a concentrated tear film

Tear Osmolarity (Tomlliinson 2006) KEEP IT SIMPLE AND TAKE ADVANTAGE OF PPV Osmolarity & Tear Film Instability in DED Two Numbers Crucial to Understand Osmolarity The DIFFERENCE b/w two eyes: 24 This tells you how stable the tear film is. Normal tears are stable and < 300 mOsm/L bilaterally. A difference of > 8 mOsm/L is a hallmark of tear instability. Tear Lab  Reimbursement – NGS:$ 44.50 – Medicaid: $ 43.50 – Commercials: $ 29-40  Code: 92071  Card cost: $10 Symptoms of Dry Eye Signs of Dry Eye PPootteennttiiaall CChhrroonniicc CChhaannggeess  Telangiectasia

 Dislocation of meibomian glands/ gland atrophy

 Scarring Treatment Recommendations by Severity Levels

Treatment Recommendations by Severity Levels

EXTEND™ Synthetic Absorbable Implant

Billing for Punctal Occlusion  68761  Punctal Occlusion Permanent or Temporary – E Codes E1 Superior Left E2 Inferior Left E3 Superior Right E4 Inferior Right – NGS reimbursement: $168.64 – Silicon Plug cost: $40-50 – Extended Collagen: $7-8

Developing Treatment Protocols  Nutritional Supplements – Omega 3 fatty acid  Fish Oil (EPA and DHA)  Flaxseed – GLA – Vitamins The Hypothesis behind “The Root Cause” of Dry Eye  Omega Imbalance (excess Omega-6:Omega-3) – causes the meibum to become thick, viscous and inflamed – causes the Meibomian Glands to become blocked – prevents the production of the lipid layer

 Without the lipid layer, the aqueous layer evaporates, causing the ocular surface to become irritated (red, dry, scratchy) Dosing Protocol – Dry Eye Omega Benefit Therapeutic Dose -Four capsules daily with meals Treatment Recommendations by Severity Levels Treatment Recommendations by Severity Levels Moderate to Severe Treatment Recommendations by Severity Levels Persistent Epithelial Defects  Treatment cyanoacrylate tarsorrhaphy – Indications  exposure dry eyes persistent epithelial defects Persistent Epithelial Defects  Treatment cyanoacrylate tarsorrhaphy – Indications lagophthalmos exposure keratitis neurotrophic keratitis dry eyes persistent epithelial defects Temporary Cyanoacrylate Tarsorrhaphies  Age (27-85) 62  Dx: – Persistent epithelial defects – Neurotrophic keratitis – Exposure keratitis – Lagophthalmos

Product Specifications PROKERA® PLUS PROKERA® SLIM Amniotic Membrane  ProKera ( Biotissue)  IOP Ocular Surface Disease Pathology Inflammation’s Effect on Healing . Inflammation: the first sign of wound healing & is also the hallmark symptom of all ocular surface diseases . Uncontrolled inflammation leads to: . Chronic pain and discomfort/irritation . Delayed healing, more tissue damage . Vision-threatening complication, e.g., scar/haze . Effective control of inflammation is an important strategy to promote healing and minimize the risk of scar/haze

Different Outcomes to Tissue Injury Scarring is more than just the risk of vision loss… Ophthalmologists Are Aware of the Importance & Challenges of treating Ocular Surface Inflammation Emerging Treatment Paradigm Emerging Therapeutic Options Amniotic Membrane Power of the Amnion KEY Amniotic Membrane Components

Recommended Pre-Treatment Tips

Published Case Review Published Case Review Case Study 3: Acute Chemical Burn Recommended Post Treatment Tips ProKera  Reimbursement – $1,628.38  Code: 65778 OOccuullooppllaassttiicc PPrroocceedduurreess ffoorr tthhee PPrriimmaarryy CCaarree CClliinniicciiaann J. James Thimons, O.D., FAAO Comprehensive Lacrimology Therapy  Includes Therapeutics – Topical – Oral  Includes Punctal Occlusion  Dilation & Irrigation  Nasolacrimal Probed  Multiple Medical Visits

PPrreeddiissppoossiinngg ffaaccttoorrss  Age  Gender  Environment  Anterior Segment Disease  Medications  CL Wear  Refractive surgery  Systemic Disease Pathophysiology of  Increased Reflex Tear Production – Rapid tear break up time – OSDI – Ocular surface irritation – Corneal changes:  Punctate epithelial erosions  Infiltrates related to staph hypersensitivity  Decreased Outflow – Punctal Stenosis – Naso-Lacrimal obstruction – Anatomic Abnormality  Floppy Lid  Ectropian/Entropian 

Managing Dacryocystitis  Antibiotic Therapy Important Penicillins  Ampicillin: Broad spectrum oral-QID dosing  Amoxicillin: Pro-drug of Ampicillin, improved absorption with lower GI side-effects  Cloxacillin/Dicloxacillin: Intrinsic beta-lactamase resistance  Augmentin: Amox + Clavulanate  Methicillin: IV prep for penicillinase producers  Amp + Sulbactam: Unasyn: IV Ticarcillin + Clavulonic acid: IV better penicillinase protection than methacillin Augmentiin Indiicatiions/Dosage forms  Indications:  Preseptal cellulitis  Dacryocystitis  Pediatric Hemophilus  Amoxicillin + Clavulanate@@@@  Dosage forms:  500 or 875mg tablets BID  125 or 250mg/5cc pediatric suspension

Plan B: The Cephalosporins  Mechanism: Same as penicillin  Bacteriostatic  Low toxicity  3% allergic to pen are allergic to Ceph.  Better penicillinase resistance than penicillins Second Generation: Greater Gram (-) activity, especially Hemophilus  Cefaclor: PO-Ceclor  Cefuroxime: PO-Ceftin

Third Generation: Reduced GR (+) activity (Staph sp) with marked Gr (-) activity  Cefixime: PO- (Suprax)  Cefpodoxime: PO - Vantin  Cefprozil: PO - Cefzil

Anatomy

Illustrative Problematic Case  60 yo white female with long standing history of associated with acne rosacea  Has been on various blepharitis regimens and seen numerous eye care providers  Continues to have daily, intermittent pooling of tears and carries tissue to wipe her eyes  Exam shows improved appearance of her lid margins Cicatricial  Chronic irritation from blepharitis and tearing can lead to cicatricial changes of eyelid skin  Chronic wiping can exacerbate age-related laxity of lid  Exposure and hypertrophy of increases tendency of lid to evert Floppy Lid Sydrome  C:\Documents and Settings\James Thimons\Desktop\photo.JPG Punctal Stenosis

Dilation & Irrigation  Equipment – Sterile saline – Pediatric/Adult dilator – 1 or 3 ml syringe – 135 degree canulla  Clinical pearl: Use antibiotic or steroid in syringe to enhance taste by patient

Naso-lacrimal Probe  Equipment – Pediatric / Adult dilator – Bowman’s probe( multiple diameters) – Sterile saline – Anesthetic – Syringe – Cannula

 ..\Desktop\photo.JPG

 ..\Desktop\photo.JPG

 ..\Desktop\photo.JPG

Mini Monoka FCI ophthalmics

Punctal/Canalicular Intubation for Punctal Stenosis  Advantages – Quick, in office procedure under topical anesthesia – In experienced hands, essentially no risk – Easy to remove  Disadvantages – Epiphora may increase over short term due to footplate occlusion of punctum – Problem may recur if underlying inflammation inadequately treated – No good billing code for procedure

Naso-Lacrimal Procedures  Re-imbursement – D&I: $143.15 – NLP: $278.61  Codes  D&I 68801  NLP 68810

Anterior Segment Surgical Procedures  Debridement  Anterior Basement Membrane Micropuncture  Complex Foreign Body Management  Cyanoacrylate Procedures

Recurrent Erosions  Pathophysiology - basal epithelial basement membrane misdirection results in: – Thickened basement membrane – Reduplicated basement membrane – Intraepithelial pseudocysts – Lack of hemidesmosomes Recurrent Erosions  Clinical Etiology – Primary Epithelial dystrophies (MDF, Meessman’s) Bowman’s membrane dystrophy (Reis-Bucklers) Stromal dystrophies (macular, lattice, granular)

Rodriiguez MM, Fiine BS, Laiibson PR, Ziimmerman LE. Diisorders of the corneall epiithelliium. A clliiniicopathollogiic study of dot, geographiic, and fiingerpriint patterns. Arch Ophthallmollogy 1974;92:475-82 Recurrent Erosions Contributing Factors –Dry eyes –Blepharitis –External disease / tear film abnormalities

The Cyclines  Tetracycline, Doxycycline and Minocycline – Isolated from Streptomyces – Effective against Gram +/ Gram -/Aerobic/ Anerobic/ Spirochetes/Rickettsia/Chlamydia – Similar action / different duration

The Cyclines  Clinical Applications – Brucellosis – Rickettsia ( Rocky Mountain Spotted fever) – Lyme Disease – Chlamydia/ – Primary Meibomianitis – Gonococcal Prophylaxis – “Corneal melting” Syndrome – Non Healing Corneal lesions – Rosacea

Recurrent Erosions Surgical Management –Epithelial debridement  curette 57 Beaver Blade

Case A

 46 y/o male physician 5 years s/p LASIK complains of decreased vision OD over past 4 years presents for refractive consultation for CXL. – Manifest

 OD +1.25-4.25 X 95 20/70 – Pachymetry

 OD 460 microns 

 file:///C:/Documents%20and%20Settings/James%20T himons/Desktop/Debridement%20video.htm Recurrent Erosions Anterior Basement Membrane Puncture –20-gauge needle

FOREIGN BODIES  CORNEAL/ CONJUNCTIVAL – HISTORY – TESTING  VA ( WITH AND WITHOUT PINHOLE)  PUPILLARY STATUS – – IRREGULAR SHAPE(OVAL)

Foreign Bodies  Superficial 65220, 65222, 65205, 67938

 Penetrating add 76529

 Perforating 76529, (65235)

FOREIGN BODIES  PENETRATING – LODGED IN TISSUE  CAREFUL INSPECTION/ REMOVAL  REFERRAL  CT SCAN  PERFORATING – HISTORY IS CRITICAL – TRIAGE/REFER

Lids and Adnexa  Lacerations 870.0 99203, (67930) – Hydrogen peroxide – Simple closure, topical and system antibiotic – Tetanus toxoid

 Ecchymosis 921.0

374.3 92081, 92285

NB: Supplemental procedures must be documented on separate forms.

Anterior Segment Procedures  Codes: – Corneal Debridement: 65435 / $91.25 – Penetrating FB: 65222/ $79.07 – Corneal FB: 65222/

Keys to Success in Complex  Betadine Prophylaxis  Pseudomembrane Debridement  Stromal HSK  Iridocyclitic HSK  Recuurent HZK Epidemic  EKC – Serotypes 8,19 most typical – Seasonal – Primarily bilateral – Atypical serotypes; Enterovirus 70  Clinical Presentation – Chemosis – Injection – Infiltrates – Ac/reaction? – FBS

EKC  Treatments – Palliative  Cold compress  Tears – Interventional  Anti-inflammatory agents  Decongestants  Combination agents  Cidofovir  Betadine  Zirgan?

EKC  Treatments – Betadine wash – Surgical Debridement

EKC Betadine Protocol  Topical anesthetic x 2  Non Alcohol betadine applied to inferior/ superior cul de sac  One minute wait  Rinse with artificial tears  Apply Topical steroids x 3-4 in post treatment period

EKC Betadine Protocol  Clinical “Pearls” – Most effective if treated within 3 days of onset – Less effective in advanced cases – SPK incidence is close to 100% – Patients will complain of FBS 1-2 hours later

ZIRGAN® ( ophthalmic gel) 0.15% The Antiviral for the 21st Century  Zirgan 0.15% Gel  Sirion Pharmaceuticals  HSK 2 years and older  Ganciclovir: Selectively targets replication of HSV DNA within corneal cells  Dose: 5 x / day till lesion resolves then tid for one week  Toxicity: – 60% blur – 20% irritation – 5% Hyperemia

ZIRGAN® Mechanism of Action Adenovirus Adenovirus clinical trial (Tabbara, 2001) Keratitis Incidence and Prevalence

ANTI-VIRALS  CLINICAL APPLICATIONS – ACUTE VS CHRONIC INFECTION – PRIMARY LESIONS – EPITHELIAL HERPES SIMPLEX – STROMAL HERPES SIMPLEX – HERPES ZOSTAR – HERPETIC IRIDOCYCLITIS Oral Antivirals

Oral Antivirals ANTI-VIRALS  SIDE EFFECTS – RENAL FAILURE/ IMPAIRMENT – HYPERSENSITIVITY REACTIONS – FACIAL EDEMA – VISUAL HALLUCINATIONS

FFaammvviirr ((ffaammcciicclloovviirr)) Pharmacology: –Synthetic nucleoside (guanine) analog, prodrug of penciclovir. Penciclovir conversion into acyclovir triphosphate inhibits herpes virus-specific polymerases & produces viral DNA termination. Formulation: –125, 250 and 500 mg tablets. Usual Dosage: –Adults: 500 mg q8h x 7 days (HZV) –Children: Safety not fully evaluated. Indications: –HZV ophthalmicus, suppression of recurrent HSV keratitis. Safety/efficacy of long-term HSV suppressive tx not fully established. ZZoovviirraaxx ((aaccyycclloovviirr)) Pharmacology: –Synthetic purine (guanosine) nucleoside analog.  Acyclovir is phosphorylated by the enzyme thymidine kinase which is encoded by herpes viruses (HSV-1, HSV-2, HZV). Acylovir triphosphate selectively inhibits herpes-specific polymerase which, in turn, produces viral DNA termination. Formulation: –400 and 800 mg tablets. Usual Dosage: –Adults: 800 mg 5x qd x 7 days (acute HZV). –Children: Safety and efficacy not fully evaluted in ocular disease mgmt. Indications: –HZV ophthalmicus, suppression of recurrent HSV keratitis. 400 mg bid for up to 1 yr. for chronic suppressive tx. (greatest benefit in recurrent, vision threatening stromal HSV keratitis or cases where vision loss from HSV epith. keratitis is a concern). VVaallttrreexx ((vvaallaaccyycclloovviirr HHCCll)) Pharmacology: –Synthetic purine (guanosine) nucleoside analog, prodrug of acyclovir. Valacyclovir is almost completely converted to acyclovir by first pass intestinal and/or hepatic metabolism. Formulation: –500 and 1000 mg tablets. Usual Dosage: –Adults: 1000 mg q8h x 7 days (HZV). –Children: Safety not fully evaluated. Indications: –HZV ophthalmicus, suppression of recurrent HSV keratitis. Safety/efficacy of long-term HSV suppressive tx not fully established, but likely comparable to acyclovir.

HSK  STROMAL KERATITIS – RULE OUT MICROBIAL DISEASE – VIROPTIC – ORAL AGENTS – – CYCLOSPORINE A – SURGERY  PKP  CONJUNCTIVAL FLAPS  TISSUE ADHESIVES

VARICELLA ZOSTAR- KERATITIS  PRIMARY INFECTION – CHICKEN POX – VACCINATION RECOMMENDED BY AMERICAN ACAD of PEDIATRICS  RECURRENT INFECTION – OPHTHALMIC INVOLVEMENT 10-255 – OPHTHLAMIC ZOSTAR > OVER AGE 60 – UNDER 40 50% IIMMUNOCOMPRIMISED

TTrraauummaa MMaannaaggeemmeenntt Blow-Out Fracture Blow-out Fracture  Symptoms – Pain (especially on attempted vertical eye movement), local tenderness, double vision, eyelid swelling, crepitus after nose blowing  Signs – Restricted eye movement, subcutaneous or conjunctival emphysema, hypesthesia in distribution of infraorbital nerve

Blow-out Fracture  Treatment – Nasal decongestants – Broad-spectrum oral antibiotics for 7 days may be used but are not mandatory – Instruct patient not to blow nose – Apply ice packs to for the first 24 to 48 hours – Surgical repair may be required Blow-out Fracture  Follow-up – Review 1 and 2 weeks after trauma, evaluate for persistent or after acute oedema has subsided – Monitor for associated ocular injuries, eg, , angle-recession – Gonioscopy and dilated examination performed 3 to 4 weeks after trauma if or micro-hyphema present TThhyyrrooiidd EEyyee DDiisseeaassee Thyroid (TED)  Inflammation and enlargement of , orbital and periorbital soft tissues  Autoimmune mediated phenomenon  Most common with hyperthyroidism, though also seen in hypothyroid and euthyroid states Thyroid Eye Disease (TED)

th th  Generally presents in 4 – 6 decade  Women 2.5-5x more frequently affected  Men usually affected more severely

 MILD – Foreign Body Sensation – Redness – Tearing

 MODERATE – Pressure sensation – Puffiness of – Worsening ocular surface discomfort

 SEVERE – Double Vision – Dyschromatopsia – Visual field loss Signs  Eyelid Retraction – Most common and characteristic sign – Upper lid may “lag” behind the on down gaze – Lower lid retraction may be present as well Signs  Ocular Surface Difficulties – Injection over rectus insertions – Conjunctival Chemosis – Punctate Keratitis – Epiphora Signs  Periorbital swelling with pronounced fat herniation

 Proptosis  Limitation of extraocular motility Diagnostic Studies  Thyroid function tests (TFTs) – Patients with TED may have normal TFTs on presentation  Orbital ultrasound or Orbital CT – Enlargement of extraocular muscle bellies with normal appearing tendons – Inferior rectus > Medial > Superior > Lateral Management Options  MILD -Artificial tears, especially with reading or computer work -Ointment at bedtime Management Options  Moderate: – Ramp up daily lubrication – Consider topical steroids – Encourage moisture chamber at bedtime – Consider surgical options Management Options  Severe: Double vision, Corneal Exposure, – Maximize lubrication for corneal issues – Short term options: Radiation, Steroids – Definitive Management: 1. Orbital Decompression 2. Surgery 3. Eyelid Retraction Repair Made Simple  Laboratory testing – Medical workup protocols

Medical Laboratory Work-Up  Indications Bilateral Recurrent Chronic Unresponsive to treatment Posterior uveitis Pediatric uveitis (under age 15) Medical Laboratory Work-Up  Pediatric - standard tests – Erythrocyte sedimentation rate (ESR) – Antinuclear antibody (ANA) – ELISA or IgG/IgM for toxoplasmosis – ELISA or IgG/IgM for lyme – FTA-ABS – VDRL or RPR Medical Laboratory Work-Up  Pediatric – TORCH if suspect infection or have posterior segment involvement  TORCH Workup – Toxoplasmosis – Other (Syphilis, Lyme) – (CMV) – Herpes simplex (HSV) Medical Laboratory Work-Up  Adult - standard tests – Complete blood count (CBC) with differential – Erythrocyte sedimentation rate (ESR) – Antinuclear antibody (ANA) – FTA-ABS – RPR or VDRL – Lyme ELISA or IgG/IgM – PPD – Chest X-ray

Medical Laboratory Work-Up  Adult - additional tests to consider depending on medical history & symptoms – Angiotension converting enzyme (ACE) – C Reactive Protein (CRP) – Lysozyme – HLA-B27 – Rheumatoid Factor – ELISA or IgG/IgM for Toxoplasmosis – S-I Joint X-ray Medical Laboratory Work-Up  Standard test panel designed to detect some of the more commonly related systemic diseases  May add or substitute tests at clinician’s discretion  Should design test strategy based on suspected diseases, not just order every possible test  Unless patient has pulmonary symptoms, may delay chest x-ray until receive the results from other tests • Need to evaluate both patient’s symptoms and laboratory values

Medical Laboratory Work-Up Medical Laboratory Work-Up Medical Laboratory Work-Up  Disease – Test Relationships – Rheumatoid arthritis (ANA, ESR, CRP, RF, HLA-B27) – Systemic lupus erythematosus (ANA, CRP, ESR) – Giant cell arteritis (ESR) – Ankylosing spondylitis (S-I joint X-ray, HLA-B27) – Inflammatory bowel (HLA-B27) – Reiter’s syndrome (HLA-B27, joint X-rays) – Syphilis (FTA-ABS, VDRL or RPR) Medical Laboratory Work-Up  Disease – Test Relationships – Sarcoidosis (ACE, chest X-ray, serum lysozyme, Gallium scan, biopsy) – Tuberculosis (PPD, chest X-ray) – Lyme disease (ELISA, IFA, IgG/IgM) – Toxoplasmosis (ELISA, IFA, IgG/IgM) – Toxocaris (ELISA, IgG/IgM) – Histoplasmosis (no accurate tests) – Herpes simplex (viral cultures, IgG/IgM) Medical Laboratory Work-Up  Disease – Test Relationships – Varicella-Zoster (IgG/IgM) – Allergy (skin test, immunoglobulin levels) – HIV/AIDS (ELISA, western blot) – Behcet’s disease (HLA-B5) – Vogt-Kayangi-Harada syndrome (HLA-DR4) Augmentiin Amoxaciilllliin/Cllavaullanate  Broad spectrum penicillin (Staph, Strep, Hemophilus  Effective against penicillinase producers-clavulanate blocks penicillinase@@@  High therapeutic index  Bacteriocidal  Low GI side-efffects  Safe in pregnancy  Watch out for allergy  Cheap***